Latest news with #TME
Yahoo
5 days ago
- Business
- Yahoo
Robust Revenue Growth, Strategic Investments Drive Gains For Tencent Music Entertainment Group (TME)
Tencent Music Entertainment Group (NYSE:) is among the 13 Best Booming Stocks to Buy Now. The stock has had impressive year-to-date returns of nearly 80%, driven by strong financial performance and positive investor sentiment resulting from a recent strategic acquisition. A singing performer silhouetted on a spotlighted online stage. The Chinese music streaming giant reported a first-quarter revenue of RMB 7.36 billion, increasing 8.7% year-over-year and surpassing forecasts of RMB 7.27 billion, due to robust growth in revenues from online music services. The company's adjusted profit of RMB 1.37 also topped estimates of RMB 1.33. Tencent Music Entertainment Group (NYSE:TME) also saw strong subscriber growth during the quarter, mainly due to its investments in long-form content, such as audiobooks and podcasts, which is helping offset the weakness in its social entertainment business. CFRA Research analyst Ahmad Halim had the following to say on the company's Q1 2025 results: 'Tencent Music's continued innovation in AI-powered personalization, long-form audio and fan-driven commerce, combined with cost discipline and increased content scale, will support margin expansion and deeper monetization through the second half of 2025.' Investor sentiment has also been bolstered by a South Korean filing late in May that revealed Tencent Music Entertainment Group (NYSE:TME) was acquiring a 9.7% stake worth $177 million in K-pop agency SM Entertainment, making it the second-largest shareholder of the company. While we acknowledge the potential of TME as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best German Stocks to Invest in Now and Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. Disclosure: None.
Malaysian Reserve
11-07-2025
- Business
- Malaysian Reserve
Malaysia Airlines Takes Centre Stage as Official Airline Partner at Travel Madness Expo 2025
KUALA LUMPUR, Malaysia, July 11, 2025 /PRNewswire/ — Malaysia Airlines is proud to announce its participation as the Official Airline Partner of the Travel Madness Expo (TME) 2025, one of the Philippines' biggest travel and trade fairs, happening from 11 July until 13 July 2025 at Hall 1-4, SMX Convention Centre, Manila. Participating in TME 2025 as the Official Airline Partner, Malaysia Airlines offers visitors exciting experiences at the travel fair and invites travellers worldwide to embrace the joy of discovery and make every trip with Malaysia Airlines a memorable journey. At the booth, visitors can explore the airline's youngest fleet, the A330neo cabin, in Virtual Reality (VR), featuring the innovative Collins Aerospace Elevation Business Class seats and the award-winning Recaro CL3810 Economy seats. On top of that, visitors can look forward to meet-and-greet sessions with the Pilot Parker mascot. In conjunction with TME, Malaysia Airlines is offering an exclusive all-in return fares starting from PHP 14,613 in Economy Class and from PHP 45,080 in Business Class, available for bookings made from 8 July until 21 July 2025, for travel from 8 July 2025 until 31 March 2026. This special deal is available exclusively via the Malaysia Airlines website and mobile app. Featured destinations include Kuala Lumpur, Paris, Auckland, Jakarta, and Singapore — inviting travellers to enjoy seamless connectivity across Malaysia Airlines' expansive network, serving as the gateway to Asia and beyond. Dersenish Aresandiran, Chief Commercial Officer of Airlines, Malaysia Aviation Group said, 'As the Official Airline Partner of TME 2025, Malaysia Airlines is proud to connect travellers to the world through our signature Malaysian Hospitality. We are excited to be part of this vibrant travel fair that inspires new adventures and memorable journeys. Whether for leisure or business, we look forward to welcoming passengers onboard for a truly warm and enriching travel experience.' To further enhance the travel experience, Malaysia Airlines continues to offer its Bonus Side Trip (BST) programme, inviting international passengers to double their adventure with a stopover in Malaysia. With this offer, travellers can enjoy a complimentary domestic return flight to one of seven exciting destinations—including Langkawi, Penang, Johor Bahru, and Kota Kinabalu— at no extra fare, just pay the taxes. Fully integrated into the international ticket fare, this initiative transforms every visit into a multi-destination experience, showcasing the beauty and diversity of Malaysia. MA. Paz Alberto, President of Travel Innovators Inc. and Chairperson of the 12th Travel Madness Expo said, 'TME has always been about connecting people to experiences that enrich their lives, and we're thrilled to have Malaysia Airlines onboard once as our Official Airline Partner. The airline also reinforces our shared mission of promoting travel that is accessible, seamless, and meaningful. We look forward to another exciting edition of TME and to welcoming travellers who are ready to explore the world again.' Visit the Malaysia Airlines booth at Travel Madness Expo (TME) 2025 or visit to book your next trip and experience our Malaysian Hospitality firsthand. About Malaysia Airlines Malaysia Airlines is the national carrier of Malaysia, offering premium and full-service travel options to, from, and within the country. As the gateway to Asia and beyond, the airline carries up to 40,000 guests daily on memorable journeys inspired by Malaysia's diverse heritage. Malaysia Airlines embodies the nation's rich traditions, cultures, and cuisines, delivering an unparalleled experience through its signature Malaysian Hospitality across every customer touchpoint. Since September 2015, the airline has been owned and operated by Malaysia Airlines Berhad. It is part of the Malaysia Aviation Group (MAG) – a global aviation organisation comprising a range of aviation and lifestyle travel solution portfolios aimed at serving global air travel needs. As a member of the oneworld® alliance, Malaysia Airlines offers enhanced connectivity to more than 900 destinations in 170 territories worldwide. For more information, visit or download the Malaysia Airlines app for the latest promotions at your fingertips. Issued by Group Communications, Malaysia Aviation Group.
Business Wire
08-07-2025
- Business
- Business Wire
TME Pharma: Termination of the Liquidity Contract
BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical stage biotechnology company focused on developing novel therapies for treatment of cancer and eye diseases, announced today the termination of the liquidity contract entered into with the brokerage firm INVEST SECURITIES (the 'Contract'). The termination became effective on July 7, 2025 after market close. This decision is part of a broader cost optimization plan following the company's refinancing and organizational restructuring in the first half of 2025. Costs have been brought down drastically and the organization will continue to reduce operational costs to extend preserve cash. The termination of the liquidity-contract is another measure to limit costs. Given the improved trading volume and healthy liquidity of TME Pharma's shares, the Company considers the liquidity contract no longer necessary. Upon closing of the liquidity account, the following resources appeared on the liquidity account: 85,812 shares €14.974,69 in cash As of the latest report, dated June 30, 2025, the following resources appeared on the liquidity account: 97,564 shares €13,549.28 in cash Resources allocated as of the date of entry into force of the liquidity contract, on October 18 th 2016 : 10,000 shares €100,000 in cash 'We are now a lean and agile organization. Since the Company decided to change strategy we can already see the positive effects with shareholders and investors.' CEO van den Ouden said. 'Only with low operational costs we can convince shareholders and investors to support the mission of TME Pharma's core mission to develop its lead drug candidates NOX-E12 and NOX-E36.' About TME Pharma TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, TME Pharma's approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA Phase 1/2 clinical trial, TME Pharma is studying its lead drug candidate NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer) in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses, and improved survival. US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma and TME Pharma was awarded fast track designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. TME Pharma has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda ® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda ® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in the United States. The company's second clinical-stage drug candidate, NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), showing potential to address fibrosis and inflammation is evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect. Further information can be found at: TME Pharma ® and the TME Pharma logo are registered trademarks. Keytruda ® is a registered trademark of Merck Sharp & Dohme Corp. Visit TME Pharma on LinkedIn and X. About the GLORIA Study GLORIA (NCT04121455) is TME Pharma's dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy and bevacizumab. About the OPTIMUS Study OPTIMUS (NCT04901741) is TME Pharma's planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients. Disclaimer Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements.' Forward-looking statements are based on TME Pharma's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma's ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law.
Business Wire
30-06-2025
- Business
- Business Wire
TME Pharma Announces New Treasury Investment Policy
BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer and eye-diseases, announced today that is has changed its treasury management investment policy to allow investment in higher-risk assets such as crypto-currency linked investments. The decision made, was possible because TME is now well positioned for the coming 12 months after it installed a new strategy and after the execution of a reorganization and a non-dilutive financing in May. TME will continue to explore various opportunities to further support TME's mission to develop new therapies for diseases with high unmet needs including its lead drug candidate NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer) in newly diagnosed brain cancer and NOX-E36 in ophthalmic diseases. This strategy aims to leverage the extensive investment expertise of the newly named CEO, Diede van den Ouden. If these treasury management activities prove successful, the company may consider broadening the corporate mission to include crypto investment activities as a means to support the R&D mission of the company after seeking appropriate regulatory and shareholder approvals necessary for such a change. 'Since I bring strong investment experience to TME, one of the ways I can support TME's mission is by better managing its treasury investments. I see a lot of investor interest in crypto holding companies, and I believe this could be an interesting opportunity for TME to leverage some of the cash not currently needed. The near-term treasury investment should increase our capacity for R&D projects aligned with the company's core mission,' said Diede van den Ouden, the newly named CEO of TME Pharma. About TME Pharma TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, TME Pharma's approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA Phase 1/2 clinical trial, TME Pharma is studying its lead drug candidate NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer) in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses, and improved survival. US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma and TME Pharma was awarded fast track designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. TME Pharma has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in the United States. The company's second clinical-stage drug candidate, NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), showing potential to address fibrosis and inflammation is evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect. Further information can be found at: TME Pharma ® and the TME Pharma logo are registered trademarks. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp. Visit TME Pharma on LinkedIn and X. About the GLORIA Study GLORIA (NCT04121455) is TME Pharma's dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy and bevacizumab. About the OPTIMUS Study OPTIMUS (NCT04901741) is TME Pharma's planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients. Disclaimer Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements.' Forward-looking statements are based on TME Pharma's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma's ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law.
Yahoo
26-06-2025
- Business
- Yahoo
Tencent Music Entertainment's (TME) Price Target Hiked to $26.20 Macquarie
Tencent Music Entertainment Group (NYSE:TME) is one of Goldman Sachs' top Chinese stock picks. On June 17, Macquarie analyst Ellie Jiang raised his stock price target to $26.20 from $17.10, reiterating an 'Outperform' rating. The analyst's bullish stance comes amid the expectation that Tencent Music Entertainment has what it takes to build a unique presence from content creation to entertainment consumption. The analyst also expects recent mergers and acquisitions to be value accretive to help drive music revenue momentum. Tencent Music Entertainment Group (NYSE:TME) operates online music and audio entertainment platforms focused on providing users with diverse and engaging music experiences. It offers music streaming, online karaoke, live streaming, and long-form audio services through popular apps like QQ Music, Kugou Music, Kuwo Music, and WeSing. While we acknowledge the potential of TME as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Biotech Stocks Screaming a Buy and 13 Best Software Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
